ATE466570T1 - Wässrige hfsh-formulierung - Google Patents

Wässrige hfsh-formulierung

Info

Publication number
ATE466570T1
ATE466570T1 AT06798894T AT06798894T ATE466570T1 AT E466570 T1 ATE466570 T1 AT E466570T1 AT 06798894 T AT06798894 T AT 06798894T AT 06798894 T AT06798894 T AT 06798894T AT E466570 T1 ATE466570 T1 AT E466570T1
Authority
AT
Austria
Prior art keywords
hfsh
formulation
aqueous
hfsh formulation
aqueous hfsh
Prior art date
Application number
AT06798894T
Other languages
English (en)
Inventor
Suk Young Choi
Hoon Sung Jeh
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37899985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE466570(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of ATE466570T1 publication Critical patent/ATE466570T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06798894T 2005-09-27 2006-09-25 Wässrige hfsh-formulierung ATE466570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050089853A KR101105871B1 (ko) 2005-09-27 2005-09-27 인 난포자극호르몬의 안정한 용액 제형
PCT/KR2006/003811 WO2007037607A1 (en) 2005-09-27 2006-09-25 Hfsh aqueous formulation

Publications (1)

Publication Number Publication Date
ATE466570T1 true ATE466570T1 (de) 2010-05-15

Family

ID=37899985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06798894T ATE466570T1 (de) 2005-09-27 2006-09-25 Wässrige hfsh-formulierung

Country Status (18)

Country Link
US (2) US20110201554A1 (de)
EP (1) EP1928413B1 (de)
JP (1) JP5364374B2 (de)
KR (1) KR101105871B1 (de)
CN (1) CN101272764B (de)
AR (1) AR056538A1 (de)
AT (1) ATE466570T1 (de)
AU (1) AU2006295570B2 (de)
BR (1) BRPI0616300A2 (de)
DE (1) DE602006014175D1 (de)
ES (1) ES2345058T3 (de)
GT (1) GT200600431A (de)
PE (1) PE20070437A1 (de)
RU (1) RU2407514C2 (de)
SA (1) SA06270332B1 (de)
TR (1) TR200801968T2 (de)
TW (1) TW200735897A (de)
WO (1) WO2007037607A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690773C (en) 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
DE202009009905U1 (de) * 2008-02-08 2009-10-29 Biogenerix Ag Flüssig-Formulierung von FSH
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102821782B (zh) * 2010-02-12 2015-07-15 印塔斯生物制药有限公司 促卵泡激素的液体配制品
EP2417982A1 (de) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisierung von Gonadotropinen
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
SG11201603142YA (en) * 2013-11-12 2016-05-30 Cadila Healthcare Ltd Formulation for gonadotropins
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
EP3091995B1 (de) 2014-01-09 2024-03-20 Sanofi Stabilisierte pharmazeutische formulierungen von insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных
JP4165718B2 (ja) * 1995-03-21 2008-10-15 ラボラトワール セローノ ソシエテ アノニム ｈＣＧ液体製剤
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
ES2208305T3 (es) * 1999-04-08 2004-06-16 Genentech, Inc. Composicion basada en polipeptidos de carga opuesta..
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CA2474698C (en) * 2002-02-08 2009-07-21 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
CN1195069C (zh) * 2002-11-28 2005-03-30 南京医科大学 人卵泡刺激素β亚基单克隆抗体的制备方法
US7741268B2 (en) * 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
DE202009009905U1 (de) * 2008-02-08 2009-10-29 Biogenerix Ag Flüssig-Formulierung von FSH

Also Published As

Publication number Publication date
AR056538A1 (es) 2007-10-10
TW200735897A (en) 2007-10-01
BRPI0616300A2 (pt) 2011-06-14
RU2407514C2 (ru) 2010-12-27
RU2008111632A (ru) 2009-10-10
CN101272764A (zh) 2008-09-24
JP5364374B2 (ja) 2013-12-11
US20110201554A1 (en) 2011-08-18
KR101105871B1 (ko) 2012-01-16
CN101272764B (zh) 2011-05-04
EP1928413B1 (de) 2010-05-05
US20160243242A1 (en) 2016-08-25
EP1928413A4 (de) 2008-12-03
AU2006295570B2 (en) 2012-08-30
WO2007037607A1 (en) 2007-04-05
KR20070035232A (ko) 2007-03-30
TR200801968T2 (tr) 2008-06-23
EP1928413A1 (de) 2008-06-11
AU2006295570A1 (en) 2007-04-05
PE20070437A1 (es) 2007-04-26
JP2009509953A (ja) 2009-03-12
SA06270332B1 (ar) 2011-01-15
DE602006014175D1 (de) 2010-06-17
GT200600431A (es) 2007-08-28
ES2345058T3 (es) 2010-09-14

Similar Documents

Publication Publication Date Title
ATE466570T1 (de) Wässrige hfsh-formulierung
ITMI20050728A1 (it) Formulazione innovativa
DE602006009656D1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü-pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
DK1928882T3 (da) (s)-n-methylnaltrexon
DK1968631T3 (da) Vaccine
DE602006014304D1 (de) Sprühvorrichtung
DE602006015684D1 (de) Sprühvorrichtung
DE602006012066D1 (de) Daraus
DE602006014297D1 (de) Sprühvorrichtung
DK1855633T3 (da) Tampon
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DK1868586T3 (da) Antiinflammatorisk formulering
DK1885805T3 (da) Vandig overtrækssammensætning
FR2895386B1 (fr) Plieuse
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
DE602006018502D1 (de) Ng
NL1031705A1 (nl) Aminozuurderivaten.
DE602006017660D1 (de) Maskenrohlinge
EP1946752A4 (de) Antiallergisches mittel
AT501523A3 (de) Estrich
ATE541837T1 (de) Oxaphenanthren-derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties